Research Results

2022/04/05Research Results

Further Good News for Treatment of Electrohypersensitivity
or Prevention of Dementia!
FPP Is Patented as Pharmaceutical Composition for Treating
Electrohypersensitivity Not Only in U.S. But Also in Japan

On February 17, 2022, FPP (Fermented Papaya Preparation) was patented as Pharmaceutical Composition for treating Electrohypersensitivity by the Japanese Patent Office (Patent No. 7026387

FPP's Effect for prevention of Electrohypersensitivity or Dementia

This patent is based on the FPP clinical study1) using FPP for "Electrohypersensitivity(EHS)" self-reporting patients by Prof. Dominique Belpomme of Paris University, France. In this study, clinical improvement was obtained in 50-60% of the cases, among which 20-35% presented major improvement that mainly consisted of the regression of cognitive symptoms such as loss of short-term memory, concentration, attention deficiencies, insomnia and fatigue. This clinical improvement was objectively supported by a statistically significant normal recovery of mean PI in the temporal lobes by using ultrasonic cerebral tomosphygmography (UCTS), evidenced by a statistically significant decrease in malondialdehyde levels in the plasma and increase in the Glutathione peroxidase activity in red blood cells.

These results supported clinical improvement objectively and scientifically and the effect of FPP on Electrohypersensitivity was proved. Decreased cerebral blood flow can be a possible cause of dementia. Since cerebral blood flow was normalized by FPP, it is expected that FPP can work not only for Electrohypersensitivity but also Dementia.
1)Irigaray, P., Catherine, G., Carine, H., Pierre, M., & Dominique, B. (2018). Beneficial effects of a Fermented Papaya Preparation for the treatment of electrohypersensitivity self-reporting patients: Results of a phase I-II clinical trial with special reference to cerebral pulsation measurement and oxidative stress analysis. Functional Foods in Health and Disease, 8(2), 122-144.